Stock Indexes Rise to Begin Week; S&P, Nasdaq Hit New All-Time Highs, Dow Hovers Near Record

Kenvue Stock Drops on Report White House Plans to Link Tylenol to Autism Risk

23 minutes ago

Shares of Tylenol maker Kenvue (KVUE) are dropping in morning trading on a report that the White House is expected to make an announcement Monday linking pregnant women’s use of the painkiller to increased risk of autism.

According to The Washington Post, Trump administration officials plan to unveil that acetaminophen, the active ingredient in Tylenol, can lead to higher risk of autism and will warn pregnant women against using the medication unless they have a fever.

The report cited four people with knowledge of the plans for the announcement plan. Health and Human Services Secretary Robert F. Kennedy Jr. has previously been widely reported as planning to unveil that the use of Tylenol during pregnancy may be one of several causes of autism.

Kenvue said that scientific studies showed that there was no link between acetaminophen and autism.

“We believe independent, sound science clearly shows that taking acetaminophen does not cause autism,” a Kenvue spokesperson said in response for comment. “We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers.”

Read the full article here.

–Nisha Gopalan

Anywhere Real Estate Stock Jumps on $10 Billion Compass Merger

55 minutes ago

Two of the biggest names in the real estate brokerage industry are joining forces.

Christie’s International parent Compass (COMP) is acquiring Anywhere Real Estate (HOUS), which owns Century 21, Coldwell Banker, and others, in an all-stock transaction that would create a firm valued at some $10 billion. The news sent Anywhere shares jumping nearly 60% in morning trading, while shares of Compass dropped.

Compass said the deal would have Anywhere investors receive 1.436 Compass shares for every one they owned. Compass priced that at $13.01 each, which is an 84% premium to Anywhere’s closing price Friday. Compass shareholders would control a 78% stake in the new company, with Anywhere investors having the other 22%. 

Compass Founder and CEO Robert Reffkin, who will be CEO of the combined firm, said that by combining “two of the best companies in our industry, while preserving the unique independence of Anywhere’s leading brands, we now have the resources to build a place where real estate professionals can thrive for decades to come.”

Read the full article here.

–Bill McColl

Oracle, T-Mobile US, Molson Coors Replacing CEOs

1 hr 9 min ago

Several prominent companies decided Monday would be a good day to set a new course.

Oracle (ORCL), T-Mobile US (TMUS), and Molson Coors Beverage (TAP) all announced new CEOs before the bell. Oracle executives Clay Magouyrk and Mike Sicilia will take over from Safra Catz, who is becoming executive vice chair; T-Mobile COO Srini Gopalan will replace CEO Mike Sievert on Nov. 1; and Molson Coors strategy chief Rahul Goyal will succeed Gavin Hattersley on Oct. 1. 

While Molson Coors’ stock has fallen 20% year-to-date, T-Mobile’s is up 7% and Oracle’s has soared 85% in 2025.

Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal

1 hr 32 min ago

Metsera (MTSR) shares skyrocketed 60% in premarket trading after Pfizer (PFE) agreed to purchase the biopharma firm for up to $7.3 billion to jump into the lucrative weight-loss drug segment. Shares of Pfizer were up slightly.

Pfizer announced that it would pay $47.50 per share in cash for all outstanding shares of Metsera, a 43% premium to Friday’s closing price. Metsera investors could receive as much as $22.50 more per share “tied to three specific clinical and regulatory milestones” for Metsera’s experimental MET-097i+MET-233i combination obesity treatment.

Pfizer noted that Mesera has a portfolio of weight-loss medicine candidates “aimed at addressing key unmet needs via fewer injections while achieving improved efficacy and tolerability.” 

Pfizer CEO Albert Bourla said the acquisition “aligns with our focus on directing our investments to the most impactful opportunities and propels Pfizer into this key therapeutic area.” In April, the company ended development of its experimental danuglipron obesity pill on concerns about potential liver damage.

The transaction is expected to close in the fourth quarter.

Shares of Metsera only began trading at the end of January, and are up 25% since then. 

–Bill McColl

Trump Says Murdochs, Dell Likely Part of Group Buying TikTok in the US

2 hr 43 min ago

President Donald Trump said that Rupert Murdoch and his son Lachlan Murdoch, as well as Dell Technologies (DELL) CEO Michael Dell, may be involved in the group buying Chinese-owned TikTok’s U.S operations.

Speaking on Fox News on Sunday, Trump also said Oracle (ORCL) co-founder Larry Ellison was part of the same group, as widely reported previously.

“You know, they’re very well-known people. And Larry Ellison is one of them. He’s involved. He’s a great guy. Michael Dell is involved. I hate to tell you this, but a man named Lachlan is involved,” Trump said, referring to Lachlan Murdoch, CEO of Fox Corp, parent company of Fox News. Trump also said that Rupert Murdoch “is probably going to be in the group” and added the buyers were all “American patriots.”

President Donald Trump in an order last week extended to mid-December the deadline under which TikTok parent ByteDance would have to sell the social media platform to a U.S.-based owner or be banned in the country over national security concerns. TikTok has around 170 million users in the U.S.

Read the full article here.

–Nisha Gopalan

U.S. Stock Futures Point Lower to Begin Week

3 hr 29 min ago

Futures tied to the Dow Jones Industrial Average were down 0.3%.

S&P 500 futures slipped 0.3%.

Nasdaq 100 futures fell 0.4%.